Non-melanoma skin cancer (NMSC) is the most frequent cancer in renal transplant recipients (RTRs). Clinical and epidemiological studies indicate that long-life immunosuppressive therapy that is essential for preventing graft rejection and obtaining adequate graft function after renal transplantation, combined with older age at transplantation, total sun burden during life, fair skin type and personal history of treated NMSC before transplantation, are the most important risk factors for NMSC development. Since RTRs are more susceptible to developing more aggressive types of skin cancers, especially squamous cell carcinoma (SCC), it is of great importance to develop cancer awareness in these patients, making them sensitive to sun protection and regular dermatologic and skin self-examination. Immunosuppressive therapy as a risk factor of high importance has to be individually tailored and, if necessary, altered in order to decrease cancer formation as much as possible, while preserving graft survival and function. Therefore, interdisciplinary approach, including primarily nephrologists and dermatologists, should be employed in follow up of RTRs, thus enabling prevention, early diagnosing and appropriate treatment of NMSC in these patients.Nemelanomski karcinomi kože najčešći su karcinomi u bolesnika s transplantiranim bubregom. Kliničke i epidemiološke studije ukazuju na to da su najvažniji čimbenici rizika za razvoj nemelanomskih karcinoma kože doživotna imunosupresivna terapija nužna za sprječavanje odbacivanja presatka i održanje njegove funkcije te starija životna dob bolesnika prilikom transplantacije, izloženost UV zrakama tijekom života, svjetliji tipovi kože i osobna anamneza preboljelog karcinoma kože prije transplantacije. Budući da su bolesnici s transplantiranim bubregom skloniji razvoju agresivnijih tipova kožnih karcinoma, osobito planocelularnog karcinoma, izrazito je važno razviti svijest bolesnika s transplantatom o povećanoj sklonosti razvoju karcinoma kože, potrebi za prevencijom te redovitim dermatološkim pregledima i samopregledima kože. Imunosupresivnu terapiju treba prilagoditi svakom pojedinom bolesniku te ju po potrebi modificirati kako bi se smanjio rizik za pojavu karcinoma uz istodobno održanje funkcije presatka. Za praćenje bolesnika s transplantiranim bubregom potreban je interdisciplinarni pristup uključujući primarno nefrologe i dermatologe kako bismo omogućili bolesnicima s transplantatom prevenciju, ranu dijagnozu i odgovarajuće liječenje karcinoma kože
